Brief Summary

Provide pre-approval single-patient Expanded Access (Compassionate Use) of elranatamab for patients with relapsed/refractory multiple myeloma

Detailed Description

In Expanded Access, treating physicians are the Sponsors

Expanded Access requests from treating physicians should be directed to
Availability will depend on location.

Temporarily not available
Individual Patients
Multiple Myeloma

Drug: Elranatamab

Eligibility Criteria

Must have relapsed/refractory multiple myeloma (RRMM) and be refractory to at least one
immunomodulatory drug, one proteasome inhibitor and one anti-CD38 antibody. Must have
evidence of disease progression after last therapy. Must have exhausted all available
treatment options accessible as local standard of care and not be eligible for
participation in any ongoing clinical trial. Additional eligibility criteria may be

Eligibility Gender
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
NCT Number
MeSH Terms
Multiple Myeloma